Walleye Capital
NBIX icon

Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Buy
+1,773
New +$263K ﹤0.01% 3178
2026
Q1 		– Sell
-90,325
Closed -$12.8M – 4765
2025
Q4 		$12.8M Buy
90,325
+67,719
+300% +$9.81M 0.04% 496
2025
Q3 		$3.17M Sell
22,606
-4,894
-18% -$663K 0.01% 1230
2025
Q2 		$3.46M Sell
27,500
-51,196
-65% -$5.87M 0.01% 1116
2025
Q1 		$8.7M Buy
78,696
+69,737
+778% +$8.83M 0.04% 499
2024
Q4 		$1.22M Sell
8,959
-79,187
-90% -$9.79M ﹤0.01% 2201
2024
Q3 		$10.2M Buy
88,146
+83,559
+1,822% +$11.5M 0.02% 685
2024
Q2 		$631K Buy
4,587
+4,037
+734% +$554K ﹤0.01% 3299
2024
Q1 		$75.9K Buy
+550
New +$75.1K ﹤0.01% 4523
2023
Q4 		– Sell
-30,713
Closed -$3.46M – 5323
2023
Q3 		$3.46M Buy
+30,713
New +$3.23M 0.01% 1313
2023
Q2 		– Sell
-15,161
Closed -$1.53M – 4690
2023
Q1 		$1.53M Buy
+15,161
New +$1.58M 0.02% 877
2022
Q2 		– Sell
-25,533
Closed -$2.39M – 2597
2022
Q1 		$2.39M Sell
25,533
-2,849
-10% -$241K 0.06% 322
2021
Q4 		$2.42M Buy
28,382
+24,582
+647% +$2.26M 0.08% 288
2021
Q3 		$364K Sell
3,800
-4,187
-52% -$395K 0.01% 929
2021
Q2 		$777K Buy
+7,987
New +$766K 0.03% 549
2020
Q2 		– Sell
-1,734
Closed -$150K – 845
2020
Q1 		$150K Sell
1,734
-7,094
-80% -$694K 0.03% 505
2019
Q4 		$949K Buy
8,828
+6,191
+235% +$648K 0.06% 439
2019
Q3 		$238K Buy
+2,637
New +$246K 0.01% 1112

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's NBIX Position: Q2 2026 in Review

Walleye Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,773 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #3178 among its holdings. This is a return to the name: Walleye Capital previously reported a position in NBIX as recently as Q4 2025.

Walleye Capital first reported a position in NBIX in Q3 2019 and has held it in 18 quarters since. The position peaked at $12.8M in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Walleye Capital held 1,773 shares of Neurocrine Biosciences worth $299K as of Q2 2026.
  • Neurocrine Biosciences was a new Walleye Capital position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3178 holding.
  • Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 18 quarters since.
  • Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.